LifeTech Scientific Corporation
LFTSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.48 | -1.10 | 2.31 | 1.79 |
| FCF Yield | 0.52% | 1.86% | 0.53% | 0.77% |
| EV / EBITDA | 23.55 | 22.78 | 20.42 | 44.61 |
| Quality | ||||
| ROIC | 3.86% | 5.97% | 10.19% | 10.31% |
| Gross Margin | 75.28% | 78.57% | 79.64% | 80.79% |
| Cash Conversion Ratio | 1.62 | 2.38 | 1.03 | 1.47 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.91% | 11.05% | 19.54% | 11.43% |
| Free Cash Flow Growth | -69.32% | 137.23% | -63.70% | -19.20% |
| Safety | ||||
| Net Debt / EBITDA | -2.29 | -3.83 | -1.85 | -2.78 |
| Interest Coverage | 98.59 | 530.86 | 594.83 | 126.00 |
| Efficiency | ||||
| Inventory Turnover | 0.61 | 0.56 | 0.93 | 1.38 |
| Cash Conversion Cycle | 579.10 | 513.56 | 337.69 | 245.67 |